These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30014095)

  • 21. LDL Cholesterol and Cardiovascular Events in a Population Network: One More Twist of an Endless Story.
    Minotti G; Camilli M
    J Pharmacol Exp Ther; 2024 Feb; 388(3):739-741. PubMed ID: 38360802
    [No Abstract]   [Full Text] [Related]  

  • 22. [CARDS confirms usefulness of LDL lowering in type 2 diabetics].
    Bern VH
    Praxis (Bern 1994); 2004 Oct; 93(44):1 p following 1830. PubMed ID: 15559908
    [No Abstract]   [Full Text] [Related]  

  • 23. [Inhibitors of PCSK9].
    Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
    Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economics of lipid lowering with HMG CoA reductase inhibitors.
    Conti CR
    Clin Cardiol; 1995 Feb; 18(2):60. PubMed ID: 7720290
    [No Abstract]   [Full Text] [Related]  

  • 25. Reductions in LDL-cholesterol and blood-pressure levels have cumulative benefits.
    Lim GB
    Nat Rev Cardiol; 2019 Nov; 16(11):650. PubMed ID: 31530886
    [No Abstract]   [Full Text] [Related]  

  • 26. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: a new class of cholesterol-lowering agents.
    Gordon DJ; Rifkind BM
    Ann Intern Med; 1987 Nov; 107(5):759-61. PubMed ID: 3662286
    [No Abstract]   [Full Text] [Related]  

  • 27. PCSK9 Inhibitors and Cardiovascular Events.
    Sabatine MS; Wasserman SM; Stein EA
    N Engl J Med; 2015 Aug; 373(8):774-5. PubMed ID: 26295078
    [No Abstract]   [Full Text] [Related]  

  • 28. PCSK9 Inhibitors and Cardiovascular Events.
    Goemann IM; Londero TM; Dora JM
    N Engl J Med; 2015 Aug; 373(8):773-4. PubMed ID: 26287856
    [No Abstract]   [Full Text] [Related]  

  • 29. PCSK9 Inhibitors and Cardiovascular Events.
    Auer J; Berent R; Primus C
    N Engl J Med; 2015 Aug; 373(8):773. PubMed ID: 26287855
    [No Abstract]   [Full Text] [Related]  

  • 30. PCSK9 Inhibitors and Cardiovascular Events.
    Robinson JG; Kastelein JJ
    N Engl J Med; 2015 Aug; 373(8):774. PubMed ID: 26287854
    [No Abstract]   [Full Text] [Related]  

  • 31. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.
    Scherer DJ; Nelson AJ; Psaltis PJ; Nicholls SJ
    Intern Med J; 2017 Aug; 47(8):856-865. PubMed ID: 28401639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk].
    Olsson AG
    Lakartidningen; 2011 Jun 1-14; 108(22-23):1240-3. PubMed ID: 21786498
    [No Abstract]   [Full Text] [Related]  

  • 34. New Drugs for Lowering LDL-Cholesterol.
    Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment with statins: lowering of cholesterol or more?].
    Rutishauser J
    Praxis (Bern 1994); 2006 Jan; 95(4):107-10. PubMed ID: 16485605
    [No Abstract]   [Full Text] [Related]  

  • 36. Meta-analysis of LDL-C Lowering and Mortality.
    Duran EK; Cook NR; Ridker PM
    JAMA; 2018 Oct; 320(14):1493. PubMed ID: 30304421
    [No Abstract]   [Full Text] [Related]  

  • 37. PCSK9 inhibitors reduce cardiovascular events, preliminary data show.
    Mayor S
    BMJ; 2015 Mar; 350():h1508. PubMed ID: 25782694
    [No Abstract]   [Full Text] [Related]  

  • 38. Meta-analysis of LDL-C Lowering and Mortality-Reply.
    Robinson JG; Navarese EP; Andreotti F
    JAMA; 2018 Oct; 320(14):1493-1494. PubMed ID: 30304424
    [No Abstract]   [Full Text] [Related]  

  • 39. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Placing PRINCE in perspective.
    Simpson RJ
    JAMA; 2001 Jul; 286(1):91-3. PubMed ID: 11434833
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.